Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Brief Summary: This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.


Options:
A: Inclusion criteria:

* Infected with documented HIV-1.
* Subjects are Abacavir-naive (subjects can be antiretroviral therapy (ART)-naive or experienced).
* All subjects must have a clinical need for treatment with Abacavir (ABC) or an ABC-containing product that precedes the decision to participate in the study.
* If subjects are therapy naive they must meet the criteria for commencing HAART according to local guidelines.
* ABC and ABC-containing products are not recommended during pregnancy. A female is eligible to enter and participate in the study if she is of:

  1. Non-child-bearing potential: women who are surgically sterile or post-menopausal, the latter indicated by history of no menses for a minimum of 1 year from the date of the screening visit.
  2. Child-bearing potential: women who provide a negative pregnancy test (beta-human chorionic gonadotrophin; beta-HCG) at Screening and who agree to one of the following methods of contraception (any contraception method must be used consistently and correctly, i.e., in accordance with both the approved product label and the instructions of a physician, during the study period and through epicutaneous patch testing where appropriate):
* Complete abstinence from intercourse from 4 weeks prior to administration of the ABC-containing compound, throughout the study, and for at least 4 weeks after discontinuation of ABC or ABC-containing product.
* Double barrier method (e.g., male condom/spermicide, male condom/diaphragm, diaphragm/spermicide). Hormonal contraceptives will not be considered sufficient forms of contraception for this study.
* Any intrauterine device with published data showing that the expected failure rate is \<1% per year.
* Sterilisation (male partner of female subject).

Exclusion criteria:

* Has previously received ABC-containing therapy.
* Satisfies any contraindications or restrictions to ABC therapy as listed in the product labels. Treatment with ABC must be in line with the recommendations of the product label.
* The subject or any of their healthcare providers is aware of the subjects HLA type.
* Has undergone an allogeneic bone marrow transplant.
* Has an active or acute CDC Clinical Category C event at screening. Treatment for the acute event must have been completed at least 30 days prior to Screening.
* Current severe illness, including liver and renal failure, major organ allograft, malignancy requiring parenteral chemotherapy that can not be discontinued for the duration of the trial, or any other conditions which, in the opinion of the Investigator, would make the patient unsuitable for the study.
* Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject's participation in the study.
* Pregnant women or women who are breastfeeding.
* Any immunisation within 30 days prior to Day 1.
* Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required.
* Subject requires treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to Screening, or has an anticipated need for these agents within the study period.
* Subject is enrolled in one or more investigational drug/vaccine protocols.
* In France, an eligible subject is neither affiliated with nor a beneficiary of a social security category.
* A subject will not be eligible for progression to Baseline (Day 1) if any of the following criteria apply:
* A positive result for HLA-B\*5701 in those subjects randomised to the genetic screening arm.
B: DISEASE CHARACTERISTICS:

* Histologically confirmed breast cancer

  * Locally advanced or inflammatory disease

    * T4a-d, any N, M0 OR
    * Any T, N2 or N3, M0
    * Large operable T2 or T3 tumors
* No bilateral breast cancer
* Frozen tumor sample available

  * 1 incisional biopsy OR
  * 2 trucut biopsies from a 14G needle
* Hormone receptor status:

  * Not specified

PATIENT CHARACTERISTICS:

Age:

* 70 and under

Sex:

* Female

Menopausal status:

* Not specified

Performance status:

* WHO 0-1

Life expectancy:

* Not specified

Hematopoietic:

* Neutrophil count greater than 1,500/mm\^3
* Platelet count greater than 100,000/mm\^3

Hepatic:

* Bilirubin less than 1.2 mg/dL
* SGOT less than 60 IU/L

Renal:

* Creatinine less than 1.35 mg/dL

Cardiovascular:

* LVEF normal by echocardiography or MUGA

Other:

* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
* No serious uncontrolled medical condition
* No uncontrolled psychiatric or addictive disorders
* Not pregnant or nursing
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* No prior chemotherapy

Endocrine therapy:

* Not specified

Radiotherapy:

* No prior radiotherapy

Surgery:

* See Disease Characteristics
C: Inclusion criteria:

* Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
* Epidermal Growth Factor Receptor mutation detected by central laboratory analysis of tumour biopsy material.
* Measurable disease according to RECIST 1.1.
* Eastern Cooperative Oncology Group score of 0 or 1.
* Age \>/= 18 years.
* Life expectancy of at least three months.
* Written informed consent that is consistent with International Conference on Harmonisation-Good Clinical Practice guidelines.

Exclusion criteria:

* Prior chemotherapy for relapsed and/or metastatic NSCLC. Neoadjuvant/adjuvant chemotherapy is permitted if at least 12 months has elapsed between the end of chemotherapy and randomisation.
* Prior treatment with Epidermal Growth Factor Receptor targeting small molecules or antibodies.
* Radiotherapy or surgery (other than biopsy) within 4 weeks prior to randomisation.
* Active brain metastases
* Any other current malignancy or malignancy diagnosed within the past five years
* Known pre-existing interstitial lung disease.
* Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom.
* History or presence of clinically relevant cardiovascular abnormalities.
* Any other concomitant serious illness or organ system dysfunction.
* Adequate absolute neutrophil count and platelet count
* Adequate liver and kidney function
* Active hepatitis B infection, active hepatitis C infection or known HIV carrier.
D: Inclusion Criteria:

* Newly diagnosed pulmonary tuberculosis patients
* Informed consent including pharmacogenomic analysis

Exclusion Criteria:

* Abnormal liver and kidney function test before treatment
* Long-term use of steroids and/or immunodepressants
* Inadequate clinical conditions

Answer: C